Amicus Therapeutics (NASDAQ:FOLD) Lowered to “Hold” Rating by StockNews.com

StockNews.com cut shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research report released on Thursday.

FOLD has been the topic of a number of other research reports. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Guggenheim increased their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. upped their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Amicus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $9.19 on Thursday. The stock’s 50-day simple moving average is $9.56 and its 200 day simple moving average is $10.41. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of -51.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.61. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics has a 52-week low of $8.78 and a 52-week high of $14.02.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Institutional investors have recently modified their holdings of the company. OLD Second National Bank of Aurora bought a new position in shares of Amicus Therapeutics during the 3rd quarter valued at about $26,000. Hazlett Burt & Watson Inc. increased its position in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the last quarter. Virtus Fund Advisers LLC bought a new position in Amicus Therapeutics during the 4th quarter worth approximately $29,000. Blue Trust Inc. grew its position in Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,831 shares during the last quarter. Finally, Arcadia Investment Management Corp MI bought a new position in Amicus Therapeutics during the 3rd quarter worth approximately $32,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.